PABAF.US Patrys Limited

Healthcare Biotechnology USA Stocks
0.0600 USD
Close of Nov 15, 2026
0.0600 0.0600
Market cap
USD 42.5M
P/E
-
P/B
38.37x
ROE
-36.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is PABAF.US undervalued?

Graham number

The Graham number of Patrys Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Patrys Limited fundamental analysis

No fundamental analysis for Patrys Limited yet.

Patrys Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Patrys Limited

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the bi…

Full company profile